X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
Details:
OPT-302 (sozinibercept) is a VEGF-C/D inhibitor, which is being evaluated in combination with aflibercept, an anti-VEGF-A therapy, for the treatment of wet Age-related Macular Degeneration (wet AMD).
Lead Product(s): Sozinibercept,Aflibercept
Therapeutic Area: Ophthalmology Product Name: OPT-302
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 14, 2024
Details:
The Company intends to use the net proceeds to fund its ongoing and planned clinical and preclinical development of our product candidates, including ongoing clinical trials for 4D-150, 4D-710, 4D-310, 4D-125 and 4D-110. 4D-150 is a dual-transgene, intravitreal gene therapy.
Lead Product(s): 4D-150,Aflibercept
Therapeutic Area: Ophthalmology Product Name: 4D-150
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Goldman Sachs & Co. LLC
Deal Size: $250.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 05, 2024
Details:
Eylea (aflibercept) is a PGF & VEGF-A inhibitor, It is being evaluated in phase 3 clinical trials for the treatment of neovascular (wet) age-related macular degeneration.
Lead Product(s): Aflibercept
Therapeutic Area: Ophthalmology Product Name: Eylea
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 24, 2024
Details:
Eylea (aflibercept) is a PGF & VEGF-A inhibitor, It is now approved in Japan for the treatment of neovascular (wet) age-related macular degeneration & diabetic macular edema.
Lead Product(s): Aflibercept
Therapeutic Area: Ophthalmology Product Name: Eylea
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 18, 2024
Details:
Eylea (aflibercept) is a PGF & VEGF-A inhibitor, It is now approved in EU for the treatment of neovascular (wet) age-related macular degeneration (nAMD).
Lead Product(s): Aflibercept
Therapeutic Area: Ophthalmology Product Name: Eylea
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 08, 2024
Details:
AVT06 (aflibercept-biosimilar) is a recombinant fusion protein which inhibits the binding and activation of VEGF receptors, neovascularization, and vascular permeability. It is being evaluated in phase 3 clinical studies for the treatment of Neovascular (Wet) AMD.
Lead Product(s): Aflibercept
Therapeutic Area: Ophthalmology Product Name: AVT06
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 03, 2024
Details:
Eylea (aflibercept) is a PGF & VEGF-A inhibitor, its 8 mg formulation is being evaluated in PULSAR clinical trial for the treatment of neovascular (wet) age-related macular degeneration (nAMD) and in PHOTON trial in diabetic macular edema (DME).
Lead Product(s): Aflibercept
Therapeutic Area: Ophthalmology Product Name: Eylea
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 10, 2023
Details:
Eylea HD(aflibercept) is a vascular endothelial growth factor (VEGF) inhibitor approved in 8mg dose for the treatment of neovascular (wet) age-related macular degeneration (AMD), various types of macular edema and diabetic retinopathy.
Lead Product(s): Aflibercept
Therapeutic Area: Ophthalmology Product Name: Eylea HD
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Bayer AG
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 18, 2023
Details:
SOK583A1 (aflibercept) is a recombinant fusion protein that bind to vascular endothelial growth factor A (VEGF-A) and placental growth factor (PlGF) used to treat neovascular (wet) age-related macular degeneration (AMD), various types of macular edema and diabetic retinopathy.
Lead Product(s): Aflibercept
Therapeutic Area: Ophthalmology Product Name: SOK583A1
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 15, 2023
Details:
Eylea (aflibercept) is a vascular endothelial growth factor (VEGF) inhibitor investigating in 8mg dose for the treatment of neovascular (wet) age-related macular degeneration (AMD), various types of macular edema and diabetic retinopathy.
Lead Product(s): Aflibercept
Therapeutic Area: Ophthalmology Product Name: Eylea
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 10, 2023
Details:
YESAFILI (aflibercept) is a vascular endothelial growth factor (VEGF) inhibitor used to treat neovascular (wet) age-related macular degeneration (AMD), various types of macular edema and diabetic retinopathy.
Lead Product(s): Aflibercept
Therapeutic Area: Ophthalmology Product Name: Yesafili
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 24, 2023
Details:
Eylea (aflibercept) is a vascular endothelial growth factor (VEGF) inhibitor used to treat Neovascular (Wet) Age-Related Macular Degeneration (AMD), various types of macular edema and diabetic retinopathy.
Lead Product(s): Aflibercept
Therapeutic Area: Ophthalmology Product Name: Eylea
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 29, 2023
Details:
Eylea (aflibercept) is a vascular endothelial growth factor (VEGF) inhibitor used to treat Neovascular (Wet) Age-Related Macular Degeneration (AMD), various types of macular edema and diabetic retinopathy.
Lead Product(s): Aflibercept
Therapeutic Area: Ophthalmology Product Name: Eylea
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 27, 2023
Details:
CLS-AX (axitinib injectable suspension) is a proprietary suspension of axitinib for suprachoroidal injection. Axitinib is a tyrosine kinase inhibitor (TKI), currently investigate for neovascular age-related macular degeneration.
Lead Product(s): Axitinib,Aflibercept
Therapeutic Area: Ophthalmology Product Name: CLS-AX
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2023
Details:
According to the agreement, Alvotech will be responsible for development and manufacture, while Polifarma will handle market registration and commercialization of AVT06, a recombinant fusion protein and a biosimilar candidate to Eylea® (aflibercept).
Lead Product(s): Aflibercept
Therapeutic Area: Ophthalmology Product Name: AVT06
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Alvotech
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement May 10, 2023
Details:
Eylea (aflibercept) is a vascular endothelial growth factor (VEGF) inhibitor used to treat Neovascular (Wet) Age-Related Macular Degeneration (AMD), various types of macular edema and diabetic retinopathy.
Lead Product(s): Aflibercept
Therapeutic Area: Ophthalmology Product Name: Eylea
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 10, 2023
Details:
The net proceeds of the offering will be used to fund the company's pre-clinical and clinical development of its product candidates, including 4D-150, is a dual-transgene, intravitreal gene therapy designed for the treatment of wet AMD.
Lead Product(s): 4D-150,Aflibercept
Therapeutic Area: Ophthalmology Product Name: 4D-150
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Goldman Sachs & Co. LLC
Deal Size: $138.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering May 09, 2023
Details:
The proceeds will fund the ongoing and planned clinical and preclinical development of company's candidates, including ongoing trials for 4D-150, 4D-710, 4D-310, 4D-125 and 4D-110. 4D-150 is a dual-transgene, intravitreal gene therapy for the treatment of wet AMD.
Lead Product(s): 4D-150,Aflibercept
Therapeutic Area: Ophthalmology Product Name: 4D-150
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Goldman Sachs & Co. LLC
Deal Size: $120.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering May 04, 2023
Details:
Eylea (aflibercept) is a vascular endothelial growth factor (VEGF) inhibitor used to treat neovascular (wet) age-related macular degeneration (AMD), various types of macular edema and diabetic retinopathy.
Lead Product(s): Aflibercept
Therapeutic Area: Ophthalmology Product Name: Eylea
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 01, 2023
Details:
Aflibercept is a vascular endothelial growth factor (VEGF) inhibitor used to treat Neovascular (Wet) Age-Related Macular Degeneration (AMD), various types of macular edema and diabetic retinopathy.
Lead Product(s): Aflibercept
Therapeutic Area: Ophthalmology Product Name: ALT-L9
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 23, 2023
Details:
ALT-L9 (aflibercept) is a vascular endothelial growth factor (VEGF) inhibitor used to treat Neovascular (Wet) Age-Related Macular Degeneration (AMD), various types of macular edema and diabetic retinopathy.
Lead Product(s): Aflibercept
Therapeutic Area: Ophthalmology Product Name: ALT-L9
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 22, 2023
Details:
Eylea (aflibercept) is a vascular endothelial growth factor (VEGF) inhibitor used to treat Neovascular (Wet) Age-Related Macular Degeneration (AMD), various types of macular edema and diabetic retinopathy.
Lead Product(s): Aflibercept
Therapeutic Area: Ophthalmology Product Name: Eylea
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 08, 2023
Details:
Eylea (aflibercept) is a vascular endothelial growth factor (VEGF) inhibitor used to treat Neovascular (Wet) Age-Related Macular Degeneration (AMD), various types of macular edema and diabetic retinopathy.
Lead Product(s): Aflibercept
Therapeutic Area: Ophthalmology Product Name: Eylea
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 06, 2023
Details:
FYB203, a biosimilar candidate to Eylea (aflibercept), which Klinge Biopharma has in-licensed from the German biosimilar developer Formycon AG, is being evaluated in a Phase 3 clinical trial in patients with Neovascular (wet) Age-Related Macular Degeneration (nAMD).
Lead Product(s): Aflibercept
Therapeutic Area: Ophthalmology Product Name: FYB203
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Coherus Biosciences
Deal Size: Undisclosed Upfront Cash: $32.5 million
Deal Type: Acquisition January 09, 2023
Details:
Eylea (aflibercept) solution for injection is a recombinant fusion protein, consisting of portions of extracellular domains of human VEGF receptors 1 and 2, fused to the Fc portion of human IgG1 and formulated as an iso-osmotic solution for intravitreal administration.
Lead Product(s): Aflibercept
Therapeutic Area: Ophthalmology Product Name: Eylea
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 11, 2022
Details:
Phase III PULSAR trial in nAMD and phase II/III PHOTON trial in DME respectively met primary endpoint of non-inferiority of Eylea (aflibercept) 8 mg extended dosing regimens for best visual acuity at week 48, compared to Eylea dosed every 8 weeks.
Lead Product(s): Aflibercept
Therapeutic Area: Ophthalmology Product Name: Eylea
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 05, 2022
Details:
EYLEA (aflibercept) is VEGF inhibitor formulated as injection for eye. It is designed to block growth of new blood vessels and decrease ability of fluid to pass through blood vessels in eye by blocking VEGF-A and PLGF, two growth factors involved in angiogenesis.
Lead Product(s): Aflibercept
Therapeutic Area: Ophthalmology Product Name: Eylea
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 21, 2022
Details:
EYLEA (aflibercept) is VEGF inhibitor formulated as injection for eye, designed to block growth of new blood vessels and decrease ability of fluid to pass through blood vessels in eye by blocking VEGF-A and placental growth factor, two growth factors involved in angiogenesis.
Lead Product(s): Aflibercept
Therapeutic Area: Ophthalmology Product Name: Eylea
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 12, 2022
Details:
PHOTON and PULSAR data presentations demonstrate Eylea (aflibercept) 8 mg led to sustained improvements in vision and anatomic measures of retinal fluid across the 48-week treatment period in both 12- and 16-week dosing regimens.
Lead Product(s): Aflibercept
Therapeutic Area: Ophthalmology Product Name: Eylea
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 30, 2022
Details:
In the randomized global Phase III study FIREFLEYE, intravitreal treatment with Eylea 0.4 mg (aflibercept) compared to laser photocoagulation in patients with retinopathy of prematurity was shown to be efficacious, safe and well tolerated.
Lead Product(s): Aflibercept
Therapeutic Area: Ophthalmology Product Name: Eylea
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 26, 2022
Details:
Aflibercept 8 mg meets primary endpoints in two global pivotal studies in nAMD and DME achieving non-inferior improvements in best corrected visual acuity to Eylea® (aflibercept 2 mg) at week 48 / Highest levels of durability seen in nAMD and DME.
Lead Product(s): Aflibercept
Therapeutic Area: Ophthalmology Product Name: Eylea
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Regeneron Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 08, 2022
Details:
AVT06 is a recombinant fusion protein and a biosimilar candidate to Eylea® (aflibercept), binds vascular endothelial growth factors (VEGF), inhibiting the binding and activation of VEGF receptors, neovascularization, and vascular permeability.
Lead Product(s): Aflibercept
Therapeutic Area: Ophthalmology Product Name: AVT06
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 07, 2022
Details:
At 2 years, in both PANORAMA and Protocol W trials, a greater proportion of patients receiving EYLEA (aflibercept) every 16 weeks experienced a ≥2-step improvement in DRSS score, along with greater reductions in risk of developing vision-threatening complications, versus sham.
Lead Product(s): Aflibercept
Therapeutic Area: Ophthalmology Product Name: Eylea
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 29, 2022
Details:
Eyes treated with aflibercept 8 mg were more likely to be dry in the center subfield on optical coherence tomography (OCT) compared to EYLEA at every timepoint measured throughout the trial after the initial monthly dosing period.
Lead Product(s): Aflibercept
Therapeutic Area: Ophthalmology Product Name: Eylea
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 11, 2022
Details:
Aflibercept showed a positive benefit-risk profile in patients with ROP treated in 27 countries worldwide in the FIREFLEYE study, the first randomized prospective clinical trial comparing aflibercept to laser in premature babies with ROP requiring treatment.
Lead Product(s): Aflibercept
Therapeutic Area: Ophthalmology Product Name: Eylea
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 10, 2021
Details:
The team’s ability to overenroll the study highlights the unmet need and the potential for GEM103 to address these suboptimal outcomes in the setting of regular anti-VEGF therapy and its subsequent depletion in CFH levels causing complement dysfunction.
Lead Product(s): GEM103,Aflibercept
Therapeutic Area: Ophthalmology Product Name: GEM103
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 13, 2021
Details:
Aflibercept is indicated to improve visual acuity in patients with neovascular age-related macular degeneration (nAMD), diabetic macular oedema, macular oedema secondary to retinal vein occlusion, and other specific neovascular retinal diseases.
Lead Product(s): Aflibercept
Therapeutic Area: Ophthalmology Product Name: SOK583A1
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 03, 2021
Details:
Eylea is a VEGF inhibitor and formulated as an eye injection. It can potentially hinder the growth of new blood vessels and lower the chances of fluid passing through blood vessels in the eye by inhibiting VEGF-A and placental growth factor (PLGF).
Lead Product(s): Aflibercept
Therapeutic Area: Ophthalmology Product Name: Eylea
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 30, 2021
Details:
As part of this strategic alliance, Cipla Gulf will be responsible for commercialization of patented biosimilars of leading products covering therapeutic categories across immunology, osteoporosis, oncology as well as ophthalmology.
Lead Product(s): Aflibercept
Therapeutic Area: Ophthalmology Product Name: AVT06
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Alvotech
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership March 02, 2021
Details:
LY09004 is a recombinant human vascular endothelial growth factor receptor antibody fusion protein ophthalmic injection (strength 11.12mg(0.278ml)/vial).
Lead Product(s): Aflibercept
Therapeutic Area: Ophthalmology Product Name: LY09004
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 08, 2021
Details:
Ocumension has been granted the exclusive right to promote and commercialize OT-702 in China. OT-702 is in phase III clinical trial and is the company's third line product to enter phase III in China.
Lead Product(s): Aflibercept
Therapeutic Area: Ophthalmology Product Name: OT-702
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Shandong Boan Biological Technology
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement October 30, 2020
Details:
The approval of Aflibercept injection for intravitreal use presents a new and alternative treatment option to currently available therapies, for patients with DME.
Lead Product(s): Aflibercept
Therapeutic Area: Ophthalmology Product Name: Eylea
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 22, 2020
Details:
Overall safety profile of OPT-302 combination therapy has continued to be favorable and has now shown consistent tolerability alone or in combination with anti-VEGF-A standard of care therapy across two eye indications.
Lead Product(s): OPT-302,Aflibercept
Therapeutic Area: Ophthalmology Product Name: OPT-302
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 27, 2020
Details:
The randomized, double-masked, parallel group, multicenter study will compare SB15 and reference Eylea on safety, efficacy, pharmacokinetics, and immunogenicity.
Lead Product(s): Aflibercept
Therapeutic Area: Ophthalmology Product Name: SB15
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 30, 2020
Details:
SB15 received the green light from health authorities in eight countries, including phase three clinical trials in South Korea and the United States. SB15 is a biosimilar candidate of Regeneron Pharmaceuticals' Eylea, to treat age-related (wet) macular degeneration (AMD).
Lead Product(s): Aflibercept
Therapeutic Area: Ophthalmology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 15, 2020
Details:
The trial met the prespecified primary efficacy endpoint with 52.8% of patients (95% CI 41-64%) achieving ≥ 5 letters gain in Best Corrected Visual Acuity (BCVA) at week 12.
Lead Product(s): OPT-302,Aflibercept
Therapeutic Area: Ophthalmology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 09, 2020
Details:
Opthea completed patient dosing and all follow-up week 12 patient visits in the Phase 2a trial evaluating the safety and efficacy of OPT-302 administered in combination with aflibercept.
Lead Product(s): OPT-302,Aflibercept
Therapeutic Area: Ophthalmology Product Name: OPT-302
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 30, 2020
Details:
First patient has received injection in the phase 2 trial of RBM-007 for the treatment of exudative age-related macular degeneration (AMD) in the United States.
Lead Product(s): RBM-007,Aflibercept
Therapeutic Area: Ophthalmology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 19, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
